Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the first patient was dosed in a Phase 1 trial of CA-170.

CA-170 is a first-in-class, orally available, small molecule that is designed to specifically target and inhibit the immune checkpoints, Programmed Death Ligand-1 (PD-L1) and V-domain Immunoglobulin Suppressor of T-cell Activation (VISTA). CA-170 is being developed under a collaboration and licensing agreement with Aurigene Discovery Technologies, Ltd.

“Today, we are pleased to announce dosing of the first patient in our Phase 1 trial of CA-170,” said Ali Fattaey, Ph.D., Curis’s president and CEO. “During the dose escalation stage of the trial, we look to characterize CA-170’s safety and activity in patients with solid tumors and lymphoma.  In the expansion stage of the trial, we expect to identify specific indications and regulatory paths for this highly differentiated drug candidate.”

Preclinical ex vivo experiments demonstrated that CA-170 induced effective proliferation and cytokine production by T cells that are specifically suppressed by PD-L1 or VISTA. In subsequent preclinical in vivo studies, CA-170 showed significant anti-tumor activity, similar to anti-PD-1 antibodies, in multiple tumor models.

In preclinical toxicology studies, CA-170 was considered to be safe when administered at multiple dose levels using a once daily oral dosing schedule.

The Phase 1 study is designed to: (1) evaluate the safety, tolerability, and pharmacokinetic profile of CA-170; (2) identify any dose-limiting toxicities; and (3) establish the recommended Phase 2 dose (RP2D) of CA-170 in patients with advanced solid tumors or lymphoma. During the expansion stage, the study is expected to assess the anti-cancer activity of CA-170 at the RP2D in patients with specified cancer types. (Original Source)

Shares of Curis are up over 4% to $1.65 in pre-market trading. CRIS has a 1-year high of $3.75 and a 1-year low of $1.25. The stock’s 50-day moving average is $1.76 and its 200-day moving average is $1.91.

On the ratings front, Curis has been the subject of a number of recent research reports. In a report issued on June 13, FBR analyst Christopher James reiterated a Buy rating on CRIS. Separately, on May 5, Cowen’s Boris Peaker assigned a Buy rating to the stock.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Christopher James and Boris Peaker have a total average return of -18.2% and 9.6% respectively. James has a success rate of 20.9% and is ranked #3862 out of 3977 analysts, while Peaker has a success rate of 44.9% and is ranked #311.

Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Its pipeline includes is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase, or HDAC, and phosphatidylinositol-3-kinase, or PI3K enzymes. The company conducts research programs both internally and through strategic collaborations.